Five-year survival, survival free from cytogenetic relapse, and cytogenetic relapse after HLA-A, B, DRB1 and DQB1-matched unrelated donor transplantation for patients ≤50 years old, who received IFN-α for 0 to 5 months before transplant, and received CMV and fungal prophylaxis after transplant (n = 48). (A) 5-year survival 87% ± 5%. (B) 5-year survival free from cytogenetic relapse 74% ± 6%. (C) 5-year cumulative incidence of relapse 13%. Four of 6 relapses followed graft failure and autologous reconstitution. The median follow-up of surviving patients is 1,128 days.